Partnership expands to develop a new treatment for pachyonychia congenita

19 Feb 2019

MedPharm and Palvella Therapeutics hope to develop the first approved treatment for PC in the US and Europe.

MedPharm has announced the expansion of their partnership with Palvella Therapeutics. To date, MedPharm has employed its specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase II/III clinical study.

Partnership expands to develop a new treatment for pachyonychia congenita

“MedPharm is very proud to be part of a collaboration with Palvella and the PC community which will potentially benefit PC patients directly. Currently this is a serious unmet medical need that has no approved treatments,” said Professor Marc Brown, MedPharm’s CSO and co-founder. “I have met many PC patients over the years and am excited to be continuing our support of Palvella and PC Project as they move closer to making a real difference to these patients’ lives.”

“We are very pleased with the expertise and the results that MedPharm have brought to Palvella’s lead development program for PC,” added Wes Kaupinen, Palvella’s President and CEO. “In addition to their rigorous scientific approach, the actions of the entire MedPharm organization, from their dedicated scientists to their senior leadership, have shown a deep commitment to working towards the betterment of patients suffering from PC.”

PC is a rare, chronically debilitating, and lifelong genetic disease in which mutated genes responsible for keratin production lead to extreme cell fragility. This dramatically limits patients’ ability to walk and perform everyday tasks. Most patients suffer from deformed nails and almost all experience some level of pain. No treatments are currently approved for PC in the US or Europe.

As it has advanced the PTX-022 project, MedPharm has remained attentive to the needs of PC patients as part of the company’s partnership with Palvella, and has attended Pachyonychia Congenita Project (PC Project) patient meetings where research is discussed and patient feedback is collected.

Read More

Related news

HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more 
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

18 May 2020

CDMO is contracted to produce multiple clinical batches from German facility

Read more 
Characterizing virus and virus-like particles

Characterizing virus and virus-like particles

12 May 2020

New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

Read more 
AI technology company launches with Novartis and Sarepta deals

AI technology company launches with Novartis and Sarepta deals

11 May 2020

Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

Read more 
Bio-Rad launches anti-certolizumab pegol antibodies

Bio-Rad launches anti-certolizumab pegol antibodies

5 May 2020

Using this critical antibody reagent at the preclinical stage of development will minimize the need to revalidate assays with different reagents at the clinical development stage.

Read more 
BERG named visionary in first-ever Frost Radar AI in Drug Discovery report

BERG named visionary in first-ever Frost Radar AI in Drug Discovery report

13 Apr 2020

The biotech pioneer is one of the first companies to develop corporate partnerships in this application of artificial intelligence (AI) for drug discovery.

Read more 
AstraZeneca incredibly excited by lung cancer treatment trial

AstraZeneca "incredibly excited" by lung cancer treatment trial

13 Apr 2020

Independent Data Monitoring Committee (IDMC) recommends unblind Phase III trial of Tagrisso 2 years ahead of schedule.

Read more 
German pharma companies are meeting the corona stress test

German pharma companies are meeting the corona "stress test"

7 Apr 2020

The head of the leading German pharmaceutical industry organization says German firms are working top-speed to find coronavirus medications.

Read more 
World’s leading biobanks join a global network to advance personalized healthcare research

World’s leading biobanks join a global network to advance personalized healthcare research

6 Apr 2020

The platform enables collaboration between pharmaceutical institutions, healthcare and academic researchers to generate valuable insights and advance medical research.

Read more 
Servier strengthens its R&D pipeline with Symphogen acquisition

Servier strengthens its R&D pipeline with Symphogen acquisition

6 Apr 2020

Symphogen becomes the antibody center of excellence within Servier.

Read more